Telix to Expand its US Operations Through the Acquisition of RLS Radiopharmacies
Shots:
- Telix has agreed to acquire RLS from RLS Group Ltd. to expand its North American manufacturing footprint and set up a next-gen. radiometal production network
- Telix will acquire RLS for $230M upfront in cash plus up to $20M in deferred cash based on performance milestones during the four-quarters. The acquisition is anticipated to conclude during Q1’25
- The acquisition will expand Telix’ US footprint through RLS’ 31 licensed radiopharmacies that will be used to set up a radiometal production & distribution network. The network will support key therapeutic & diagnostic isotopes plus will utilize Telix’s ARTMS QUANTM Irradiation System (QIS) cyclotron technology for efficient radiometal production
Ref: Telix Pharmaceuticals | Image: Telix & RLS Radiopharmacies
Related News:- Telix to Acquire QSAM Biosciences to Enhance its Oncology Segment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
